China's economy accelerates blood, drives drug machine industry into "fast track"

The National Bureau of Statistics recently released july manufacturing PMI data of 51.1, up from 0.2 percentage points the previous month.
combined, manufacturing output has been in the expansion zone for five months in a row, with the July production index at its highest level since February 2011.
in addition, the China Economic and Social Commission's "China's Manufacturing High Quality Development Report (2019)" also shows that China's manufacturing development process is accelerating and the scale of investment is expanding.
in the first three quarters of this year, investment in high-tech manufacturing grew by 12.6% YoY, investment in technological transformation in manufacturing industry increased by 8.9%, and value added of industrial strategic emerging industries and high-tech manufacturing increased by 8.4% YoY and 8.7% YoY.
based on this, enterprises are generally optimistic about the growth prospects of the manufacturing industry, think that the next market demand will further strengthen.
manufacturing industry development is moving forward steadily, the pharmaceutical equipment industry will benefit from the data, China's manufacturing industry is steadily recovering.
and in this context, the pharmaceutical equipment industry as an important part of China's manufacturing industry, with the volume of procurement, medical insurance input, as well as the expansion of medical consumption demand, the pharmaceutical industry is facing capacity upgrading, in the pharmaceutical companies need to increase production capacity to adapt to market demand and other factors, will also usher in further development.
in fact, according to the author understand that there are a number of pharmaceutical equipment listed companies disclosed the 2020 half-year report, and the performance is expected.
, such as Canaan Technology recently disclosed the half-yearly report, said that the first half of 2020 is expected to make a profit of 27.2618 million yuan - 32.7141 million yuan, the company in 2019 the same period of profit of 18.1745 million yuan, an increase of 50%-80% year-on-year.
for the reasons for the change in performance, Canaan Technology believes that the main reporting period, the company actively take all effective measures, one-handed epidemic prevention, one-handed production, to protect some downstream customers pharmaceutical enterprises and logistics industry epidemic-related products supply, only to lead to the company's sales growth, while improving operating efficiency, to ensure a steady growth of operating performance.
in addition, Dongfulong's newly disclosed first-quarter 2020 results in April 2020 also forecast that the net profit attributable to shareholders of listed companies will reach 46.1956 million yuan - 5097.44 million yuan, up 190%-220% yoy year-on-year.
industry believes that the above data fully show that the first half of this year, China's pharmaceutical equipment industry showed a good development trend, the head of enterprises will benefit from a steady increase.
pharmaceutical equipment industry needs to accelerate the transformation and upgrading at present, although the domestic economy is continuing to warm up, the development of the pharmaceutical industry also continued to improve, but under the influence of the volume procurement, consistency evaluation, new health insurance and other policies, the pharmaceutical industry pattern is also undergoing major changes, pharmaceutical companies face new demands such as capacity upgrading, the industry is expected to in this situation, the domestic pharmaceutical equipment industry will also usher in geometric growth.
and the technical level of pharmaceutical equipment determines the level of pharmaceutical, so pharmaceutical equipment enterprises in the face of opportunities at the same time also need to meet the challenges of transformation and upgrading, need to continuously strengthen research and development investment, and continue to innovate technology.
in fact, the current domestic pharmaceutical equipment enterprises are not only constantly strengthening the investment in research and development innovation, but also in accordance with the needs of pharmaceutical companies to personalize product design and layout.
the author learned that there are pharmaceutical machine enterprises on the purpose of the supply of the belt, put forward the "4 plus 7" centralized water supply overall solution.
the preparation capacity of the scheme is 25T/h of purified water and 16T/h of injectable water, which can meet the water demand of six production lines in three workshops at the same time.
also has pasteurization, low-pressure circulation and two-way water supply and other functions.
the relevant person in charge of the enterprise said that after the implementation of the volume procurement policy, system intelligence will be the mainstream trend of pharmaceutical production in the future, some pharmaceutical companies will be more intelligent construction standards, as well as less human and unmanned trend development, and these are inseparable from the overall planning and consideration.
in addition, there are powder equipment manufacturers are relying on sufficient experience, in helping a large number of pharmaceutical companies to establish a better production system, such as product automation, intelligence, the entire bulk processing equipment and software combination.
and is actively exploring new areas while consolidating the market with technical experience.
it is understood that in 2019 the company contracted a large domestic pharmaceutical company to supply almost all of the new plant of API.
conclusion, for the pharmaceutical equipment industry prospects, drug machine people generally expressed optimism.
the future, driven by many favorable policies of medicine, China's innovative pharmaceutical industry development prospects are broad, pharmaceutical equipment enterprises in the face of major consolidation, the elimination of low value-added backward equipment, but also will usher in more opportunities and market competition.
in this case, domestic pharmaceutical machine enterprises also need to continue to carry out technological innovation, stabilize product performance, improve product technology and quality, in order to rely on high-end, cost-effective products to win more markets.
.